1 |
NCT00310115 |
Completed |
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Behavioral: Smoking Prevention Usual Care
- Behavioral: Counseling Intervention
|
Observational |
|
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of Patients with Smoking Abstinence
- Number of Cigarettes Smoked Daily
|
469 |
Female |
18 Years and older (Adult, Senior) |
NCT00310115 |
BS01-178 R01CA089350 P30CA016672 MDA-BS01-178 CDR0000466327 NCI-2010-01136 |
|
April 2002 |
August 2016 |
August 2016 |
April 3, 2006 |
September 23, 2016 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
2 |
NCT02897778 |
Completed |
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors |
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- (and 12 more...)
|
- Drug: Entinostat
- Other: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline on heart rate (HR) when entinostat is given at a supratherapeutic dose
- Change from baseline on electrocardiogram procedures when entinostat is given at a supratherapeutic dose
- Incidence of treatment-emergent adverse events (TEAES) and serious adverse events (SAEs)
- (and 11 more...)
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT02897778 |
SNDX-275-0140 |
|
August 2016 |
March 2017 |
April 2017 |
September 13, 2016 |
April 17, 2017 |
|
- The START Center for Cancer Care
San Antonio, Texas, United States
|
3 |
NCT02495103 |
Recruiting |
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma |
- Renal Cell Carcinoma
- Hereditary Leiomyomatosis and Renal Cell Cancer
- Papillary Renal Cell Carcinoma, Sporadic
|
- Drug: Vandetanib
- Drug: Metformin
- Drug: Vandetanib/Metformin
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 Component: To establish the safety and maximum tolerated dose (MTD) of vandetanib and metformin when used in combination in patients with metastatic RCC.
- Phase 2 Component: To determine the overall response rate (RECIST 1.1) following treatment with the combination of vandetanib and metformin in patients with 1) advanced RCC associated with HLRCC or SDH, and 2) advanced sporadic/non-HLRCC papilla...
- Phase 1 Component: Evaluate the clinical activity of the combination of vandetanib and metformin
- (and 6 more...)
|
73 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02495103 |
150157 15-C-0157 |
|
July 8, 2015 |
May 1, 2021 |
May 1, 2022 |
July 13, 2015 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
4 |
NCT01253668 |
Completed |
Brivanib Metastatic Renal Cell Carcinoma |
- Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
|
- Drug: Brivanib alaninate
- Genetic: Polymerase chain reaction
- Other: Iodine I 124 chimeric monoclonal antibody G250
- (and 3 more...)
|
Interventional |
Phase 2 |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Best overall response rate dfor each patients as assessed by RECIST 1.1 guidelines
- Overall survival
- (and 7 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT01253668 |
UPCC 04810 |
|
November 2010 |
September 2013 |
September 2013 |
December 3, 2010 |
December 15, 2015 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
5 |
NCT00069160 |
Completed Has Results |
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer |
- Lung Neoplasms
- Ovarian Neoplasms
- Cervix Neoplasms
- Renal Neoplasms
|
- Drug: docetaxel
- Drug: tariquidar
- Other: 99mTc-sestamibi imaging
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Geometric Mean of Maximum Concentration of the Drug (Cmax)
- The Number of Participants With Adverse Events.
- Geometric Mean of Area Under Curve (AUC0)-24
- (and 3 more...)
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT00069160 |
030284 03-C-0284 |
|
September 2003 |
December 2009 |
December 2009 |
September 16, 2003 |
October 12, 2012 |
October 12, 2012 |
- National Institutes of Health
Bethesda, Maryland, United States
|
6 |
NCT02111850 |
Recruiting |
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive |
- Cervical Cancer
- Renal Cancer
- Urothelial Cancer
- (and 2 more...)
|
- Biological: Anti-MAGE-A3-DP4 TCR
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Aldesleukin
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of treatment related adverse events
- Response Rate
- Measure Persistence
|
107 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02111850 |
140052 14-C-0052 |
|
April 9, 2014 |
December 29, 2023 |
December 27, 2024 |
April 11, 2014 |
March 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
7 |
NCT00123773 |
Completed |
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence |
- Sarcoma
- Multiple Myeloma
- Testicular Neoplasms
- (and 2 more...)
|
- Procedure: Positron Emission Tomography
|
Interventional |
Phase 2 |
- AHS Cancer Control Alberta
- Cross Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To confirm the diagnostic effectiveness of 18F-FDG in patients with known or suspected carcinoma
- To determine the clinical relevance of PET scans within these patient groups
|
1075 |
All |
15 Years and older (Child, Adult, Senior) |
NCT00123773 |
SP-14-0038/DX-FDG-003/21386 |
|
April 2004 |
December 2008 |
December 2008 |
July 26, 2005 |
February 26, 2016 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
8 |
NCT00381173 |
Completed |
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing |
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- (and 2 more...)
|
- Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.
- Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT00381173 |
ZYC3-002 |
|
November 2006 |
October 2008 |
October 2008 |
September 27, 2006 |
May 14, 2013 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - M. D. Anderson Cancer Center
Houston, Texas, United States
|
9 |
NCT00588276 |
Completed |
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors |
- Cervical Cancer
- HEENT Cancer
- Renal Cancer
- (and 3 more...)
|
- Radiation: 124I-Iodo-Azomycin Galacto-Pyranoside
|
Interventional |
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To describe imaging findings in human cancer with the new hypoxia tracer 124IAZGP and PET/CT
- To evaluate the biodistribution of 124IAZGP using serial PET imaging and to estimate blood radioactivity
- To obtain further human dosimetry data with 124IAZGP
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT00588276 |
05-023 |
|
June 2005 |
June 2012 |
June 2012 |
January 8, 2008 |
December 24, 2015 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
10 |
NCT02153905 |
Recruiting |
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive |
- Breast Cancer
- Cervical Cancer
- Renal Cancer
- (and 2 more...)
|
- Drug: Aldesleukin
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated cell dose (MTD)
- Response Rate
- Frequency of treatment related adverse events
- Engineered cell survival
|
102 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02153905 |
140110 14-C-0110 |
|
May 31, 2014 |
December 29, 2023 |
December 27, 2024 |
June 3, 2014 |
February 22, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
11 |
NCT00002641 |
Completed |
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma |
- Endometrial Cancer
- Kidney Cancer
- Ovarian Cancer
- (and 2 more...)
|
- Biological: filgrastim
- Drug: doxorubicin hydrochloride
- Drug: ifosfamide
- (and 4 more...)
|
Interventional |
Phase 3 |
- European Organisation for Research and Treatment of Cancer - EORTC
- NCIC Clinical Trials Group
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
350 |
All |
16 Years to 69 Years (Child, Adult, Senior) |
NCT00002641 |
EORTC-62931 CAN-NCIC-SR3 |
|
February 1995 |
February 2006 |
June 2012 |
January 27, 2003 |
August 8, 2014 |
|
- Karl-Franzens-University Graz
Graz, Austria - Institut Jules Bordet
Brussels, Belgium - Hopital Universitaire Erasme
Brussels, Belgium - (and 42 more...)
|
12 |
NCT00034281 |
Completed |
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 |
- Breast Neoplasm
- Pancreatic Neoplasm
- Lung Neoplasm
- (and 2 more...)
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Maximum Tolerated Dose
- Optimal Dosing for Phase II Studies.
- (and 2 more...)
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT00034281 |
01-01-TL-165-001 U1111-1127-6123 |
|
June 2002 |
September 2003 |
September 2003 |
April 25, 2002 |
February 2, 2012 |
|
- Arizona Cancer Center
Scottsdale, Arizona, United States - The Institute for Drug Development
San Antonio, Texas, United States - Brooke Army Medical Center/Drug Development Unit
San Antonio, Texas, United States - South Texas VA, Audie Murphy Division
San Antonio, Texas, United States
|
13 |
NCT01447199 |
Recruiting |
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) |
- Bladder Cancer
- Colorectal Cancer
- Endometrial Cancer
- (and 3 more...)
|
- Behavioral: Health and Diet Questionnaire
|
Observational |
|
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Time to Onset for Colorectal Cancer
|
2000 |
All |
18 Years and older (Adult, Senior) |
NCT01447199 |
DM94-060 |
|
September 1994 |
September 2019 |
September 2019 |
October 6, 2011 |
January 17, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
14 |
NCT02669914 |
Active, not recruiting |
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors |
- Non-Small Cell Lung Cancer
- Nonsmall Cell Lung Cancer
- Breast Cancer
- (and 15 more...)
|
|
Interventional |
Phase 2 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate of intracranial disease
- Safety of MEDI4736 in advanced solid epithelial-derived tumor patients with brain metastases as measured by frequency and grade of treatment-emergent adverse events
- Overall disease control rate of intracranial disease
- (and 10 more...)
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT02669914 |
201602169 |
|
September 12, 2016 |
September 21, 2017 |
December 31, 2021 |
February 1, 2016 |
November 24, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
15 |
NCT01896778 |
Completed |
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer |
- Adult Liver Carcinoma
- Breast Carcinoma
- Colon Carcinoma
- (and 7 more...)
|
- Procedure: Hyperthermia Treatment
- Other: Laboratory Biomarker Analysis
|
Interventional |
Not Applicable |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes in tumor vascular (blood flow, blood volume)
- Changes in tumor vascular measures
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT01896778 |
I 229812 NCI-2013-01198 P30CA016056 |
|
October 4, 2013 |
February 23, 2018 |
February 23, 2018 |
July 11, 2013 |
February 27, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
16 |
NCT02900248 |
Recruiting |
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice |
- Neoplasms
- Lung Neoplasms
- Colon Neoplasms
- (and 22 more...)
|
- Other: Provider determined
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Best Overall Response
- Time to Treatment Progression
- Overall Survival
- (and 2 more...)
|
100000 |
All |
18 Years and older (Adult, Senior) |
NCT02900248 |
N1OR |
N1 |
October 2, 2017 |
October 2021 |
October 2024 |
September 14, 2016 |
October 4, 2017 |
|
- Teton Cancer Institute
Idaho Falls, Idaho, United States
|
17 |
NCT00659568 |
Completed |
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma |
- Breast Cancer
- Endometrial Cancer
- Kidney Cancer
- (and 3 more...)
|
- Drug: metformin hydrochloride
- Drug: temsirolimus
|
Interventional |
Phase 1 |
- London Health Sciences Centre
- National Cancer Institute (NCI)
|
Other |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose and recommended phase II dose of metformin hydrochloride when administered with temsirolimus
- Toxicity and safety, with particular reference to glucose and lipid deregulation
- Antitumor activity, including tumor response rate and time to progression
- (and 3 more...)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT00659568 |
CAN-LRCC-UWOREB13877 CDR0000593360 WYETH-CAN-LRCC-UWOREB13877 |
|
March 2008 |
February 2010 |
August 2010 |
April 16, 2008 |
May 30, 2013 |
|
- London Regional Cancer Program at London Health Sciences Centre
London, Ontario, Canada
|
18 |
NCT00002764 |
Completed |
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma |
- Endometrial Cancer
- Kidney Cancer
- Metastatic Cancer
- (and 3 more...)
|
- Biological: filgrastim
- Drug: doxorubicin hydrochloride
- Drug: ifosfamide
- Procedure: conventional surgery
|
Interventional |
Phase 3 |
- European Organisation for Research and Treatment of Cancer - EORTC
- Eastern Cooperative Oncology Group
- Scandinavian Sarcoma Group
- Southwest Oncology Group
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
340 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00002764 |
EORTC-62933 E-EORTC-62933 SSG-EORTC-62933 SWOG-EORTC-62933 |
|
April 1996 |
November 2000 |
|
April 22, 2004 |
July 11, 2012 |
|
- Lund University Hospital
Lund, Sweden
|
19 |
NCT00531284 |
Completed Has Results |
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma |
- Ovarian Cancer
- Renal Cancer
- Non-small Cell Lung Cancer
- (and 4 more...)
|
- Drug: Carfilzomib
- Drug: Dexamethasone
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)
- Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles
- Percentage of Participants With an Overall Response Throughout the Study
- (and 11 more...)
|
184 |
All |
18 Years and older (Adult, Senior) |
NCT00531284 |
PX-171-007 |
|
September 2007 |
October 2014 |
May 22, 2017 |
September 18, 2007 |
August 15, 2017 |
December 9, 2015 |
- Pinnacle Oncology
Scottsdale, Arizona, United States - Tower Cancer Research Foundation
Beverly Hills, California, United States - Northwestern University
Chicago, Illinois, United States - (and 4 more...)
|
20 |
NCT01444456 |
Completed Has Results |
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia |
- Anemia
- Breast Cancer
- Cancer
- (and 11 more...)
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL
- Percentage of Participants by Tumor Type With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL
- Mean Change From Baseline in FACT-F Score for Participants With a VAS Improvement of 5 ± 3 Points
- (and 3 more...)
|
1262 |
All |
18 Years and older (Adult, Senior) |
NCT01444456 |
20101123 |
|
October 2011 |
August 2013 |
|
September 30, 2011 |
March 20, 2017 |
August 15, 2014 |
- Research Site
Graz, Austria - Research Site
Innsbruck, Austria - Research Site
St Poelten, Austria - (and 115 more...)
|
21 |
NCT00620295 |
Completed |
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors |
- Breast Cancer
- Colorectal Cancer
- Head and Neck Cancer
- (and 6 more...)
|
- Drug: bortezomib
- Drug: gemcitabine hydrochloride
|
Interventional |
Phase 1 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of bortezomib and gemcitabine
- Toxicity
- Disease response as measured by RECIST criteria
- Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors")
|
17 |
All |
70 Years and older (Senior) |
NCT00620295 |
CDR0000586510 UMN-2006LS040 UMN-X05227 x464 |
|
March 2007 |
February 2009 |
October 2009 |
February 21, 2008 |
November 29, 2017 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
22 |
NCT02431676 |
Active, not recruiting |
Survivorship Promotion In Reducing IGF-1 Trial |
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- (and 8 more...)
|
- Drug: Metformin
- Behavioral: Coach Directed Behavioral Weight Loss
- Behavioral: Self-control weight loss
|
Interventional |
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- IGF-1 levels
- IGF-1 levels :IGFBP3 levels (Ratio)
|
121 |
All |
18 Years and older (Adult, Senior) |
NCT02431676 |
J14148 IRB00035653 |
SPIRIT |
May 2015 |
June 2018 |
December 2018 |
May 1, 2015 |
April 18, 2018 |
|
- Johns Hopkins ProHealth
Baltimore, Maryland, United States
|
23 |
NCT03053466 |
Recruiting |
CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors |
- Solid Tumor
- Advanced Cancer
- ColoRectal Cancer
- (and 10 more...)
|
|
Interventional |
Phase 1 |
- CBT Pharmaceuticals (Australia) Pty Ltd
- Novotech (Australia) Pty Limited
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors
- Determine the recommended Phase 2 dose and schedule
- Area under the plasma concentration versus time curve (AUC)
- (and 7 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03053466 |
CBT-501-01 |
|
March 27, 2017 |
February 2018 |
March 2019 |
February 15, 2017 |
February 8, 2018 |
|
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - Cabrini Education and Research Precinct
Malvern, Victoria, Australia - Nucleus Network
Melbourne, Victoria, Australia - Linear Clinical Research
Nedlands, Western Australia, Australia
|
24 |
NCT02465892 |
Completed |
Pillars4Life Trial |
- Breast Cancer
- Lung Cancer
- Esophageal Cancer
- (and 9 more...)
|
|
Interventional |
Not Applicable |
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Supportive Care
|
- Chronic pain
- Stress
- Anxiety
|
284 |
All |
18 Years and older (Adult, Senior) |
NCT02465892 |
Pro00061381 |
Pillars4Life |
May 2015 |
October 2016 |
October 2016 |
June 9, 2015 |
July 2, 2017 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
25 |
NCT02292914 |
Unknown † |
Prospective Analysis of Robot-Assisted Surgery |
- Esophageal Cancer
- Gastric Cancer
- Pancreatic Cancer
- (and 7 more...)
|
- Procedure: Robot-assisted surgery
- Procedure: Conventional Surgery
|
Interventional |
Not Applicable |
- Instituto do Cancer do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Postoperative Complications
- ICU and hospital length of stay
|
1120 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02292914 |
NP433/13 |
|
March 2014 |
November 2016 |
November 2017 |
November 18, 2014 |
February 24, 2016 |
|
- Instituto do Câncer de São Paulo - ICESP
São Paulo, Brazil
|
26 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054 EAY131 U10CA180820 U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1211 more...)
|
27 |
NCT02012699 |
Recruiting |
Integrated Cancer Repository for Cancer Research |
- Pancreatic Cancer
- Thyroid Cancer
- Lung Cancer
- (and 44 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC)
- Procurement and banking of excess biological material for future analysis
|
9999 |
All |
19 Years to 110 Years (Adult, Senior) |
NCT02012699 |
UNMC 253-13 |
iCaRe2 |
November 2013 |
December 2099 |
December 2099 |
December 16, 2013 |
May 9, 2017 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - Penrose Cancer Center
Colorado Springs, Colorado, United States - Halifax Health Medical Center d/b/a Halifax Health
Daytona Beach, Florida, United States - (and 67 more...)
|
28 |
NCT00957424 |
Completed Has Results |
Acceptability of Less Harmful Alternatives to Cigarettes |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Behavioral: telephone-based intervention
- Drug: nicotine replacement therapy
- Other: informational intervention
- (and 2 more...)
|
Interventional |
Not Applicable |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs)
- Number of Participants Willing to Try HRPs
- Number of Participants That Completed 1-week Trial
- Number of Participants Willing to Continue With Preferred HRP
|
67 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00957424 |
CDR0000648665 P30CA016056 RPCI-I-118207 |
|
June 2009 |
August 2009 |
November 2011 |
August 12, 2009 |
February 7, 2017 |
December 14, 2016 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
29 |
NCT00790569 |
Completed Has Results |
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Drug: nicotine
- Drug: varenicline
- Other: placebo
|
Interventional |
Not Applicable |
- Butler Hospital
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Self- Reported 7-day Abstinence
- Carbon Monoxide (CO)-Confirmed 7-day Abstinence
- Rates of Smoking Cessation Continuous From First Quit Day to 6 Months
- (and 9 more...)
|
315 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00790569 |
CDR0000616663 R01CA129226 BUTLER-0807-004 |
|
September 2008 |
October 2012 |
October 2012 |
November 13, 2008 |
October 20, 2017 |
February 3, 2014 |
- Rhode Island Hospital Comprehensive Cancer Center
Providence, Rhode Island, United States
|
30 |
NCT00666978 |
Completed Has Results |
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Behavioral: smoking cessation intervention
- Drug: bupropion hydrochloride
- Genetic: gene expression analysis
- (and 4 more...)
|
Interventional |
Phase 4 |
- Lisa Sanderson Cox, PhD
- National Cancer Institute (NCI)
- University of Kansas Medical Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months
- Number of Slow and Fast Metabolizers by Metabolite Ratio
- Number of Participants for Each CYP2B6 Allele
- Number of Slow and Fast Metabolizers by Genotype
|
540 |
All |
18 Years and older (Adult, Senior) |
NCT00666978 |
10332 R01CA091912 KUMC-HSC-10332 KUMC-070313 |
|
December 2007 |
June 2010 |
June 2010 |
April 25, 2008 |
November 13, 2017 |
July 24, 2017 |
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, United States - Swope Health Central
Kansas City, Missouri, United States
|
31 |
NCT00534001 |
Completed Has Results |
Bupropion in Helping Adults Stop Smoking |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Drug: bupropion hydrochloride
- Other: placebo
|
Interventional |
Phase 2 |
- Roswell Park Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Prequit Change in Cigarettes Per Day
- Abstinence
|
95 |
All |
18 Years to 65 Years (Adult) |
NCT00534001 |
CDR0000565103 I 57805 |
|
January 2006 |
May 2008 |
July 2015 |
September 24, 2007 |
May 30, 2017 |
May 30, 2017 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
32 |
NCT00376987 |
Completed |
Zinc Supplements in Lowering Cadmium Levels in Smokers |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Dietary Supplement: zinc oxide
|
Interventional |
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction of cadmium levels
- Serum levels of cotinine, zinc, and cadmium at 3 pre-supplementation visits and at 6 supplementation visits
- Correlation of increased cadmium levels with decreased mismatch repair
- Reversal of cadmium-induced inhibition of mismatch repair
|
61 |
All |
21 Years to 120 Years (Adult, Senior) |
NCT00376987 |
CDR0000495325 CCCWFU-98903 CCCWFU-BG03-538 |
|
December 2003 |
October 2006 |
June 2015 |
September 15, 2006 |
May 30, 2017 |
|
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
|
33 |
NCT00365508 |
Completed Has Results |
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking |
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 8 more...)
|
- Drug: nicotine lozenge
- Drug: nicotine patch
|
Interventional |
Phase 4 |
- Fox Chase Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 24-hour Point Prevalence Abstinence at the 6-month Follow up
- Rate of Compliance During the First 2 Weeks
|
642 |
All |
18 Years and older (Adult, Senior) |
NCT00365508 |
CDR0000491296 FCCC-FCRB-04-003-P 05-818 |
|
February 2006 |
August 2009 |
August 2009 |
August 17, 2006 |
March 29, 2016 |
January 30, 2013 |
- Howard University Cancer Center
Washington, District of Columbia, United States - CCOP - Mount Sinai Medical Center
Miami Beach, Florida, United States - Medical College of Georgia Cancer Center
Augusta, Georgia, United States - (and 7 more...)
|
34 |
NCT02601950 |
Recruiting |
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma |
- Malignant Rhabdoid Tumors (MRT)
- Rhabdoid Tumors of the Kidney (RTK)
- Atypical Teratoid Rhabdoid Tumors (ATRT)
- (and 8 more...)
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with objective response using disease appropriate standardized response criteria
- Progression-free survival (PFS) rate for Cohort 2 (Relapsed/Refractory Synovial Sarcoma)
- Assess the effects of tazemetostat on tumor immune priming for Cohort 6
- (and 16 more...)
|
250 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02601950 |
EZH-202 |
|
December 2015 |
December 2018 |
December 2018 |
November 11, 2015 |
March 22, 2018 |
|
- University of California San Francisco
San Francisco, California, United States - University of Colorado Denver
Aurora, Colorado, United States - Mayo Clinic - Jacksonville
Jacksonville, Florida, United States - (and 29 more...)
|
35 |
NCT00638898 |
Active, not recruiting |
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
- Solid Tumor
- Adult Central Nervous System Germ Cell Tumor
- Adult Rhabdomyosarcoma
- (and 27 more...)
|
- Drug: busulfan
- Drug: melphalan
- Drug: topotecan hydrochloride
- (and 5 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment feasibility in terms of investigational agent-related adverse events of a novel treatment combination followed by peripheral blood stem cell rescue
- Overall survival
- Disease-free survival
- (and 2 more...)
|
25 |
All |
6 Months to 40 Years (Child, Adult) |
NCT00638898 |
03112 NCI-2009-01600 |
|
December 11, 2006 |
April 2019 |
April 2019 |
March 19, 2008 |
March 8, 2018 |
|
- City of Hope
Duarte, California, United States
|
36 |
NCT00408681 |
Completed Has Results |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 111 more...)
|
- Drug: lithium carbonate
- Other: laboratory biomarker analysis
|
Interventional |
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Functional Recovery
- Duration of Treatment With the Study Product
- Mucosal Anatomic Recovery
- (and 4 more...)
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00408681 |
2080.00 NCI-2010-00269 |
GVHD |
June 2006 |
November 2010 |
May 1, 2015 |
December 7, 2006 |
March 7, 2017 |
January 20, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
37 |
NCT01130519 |
Recruiting |
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer |
- HLRCC
- Metastatic Papillary RCC
|
- Drug: Bevacizumab
- Drug: Erlotinib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Progression-free survival, duration of response, and overall survival.
- Effect on potential biomarkers of angiogenesis in plasma such as VEGF and soluble VEGFR2.
- (and 5 more...)
|
85 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01130519 |
100114 10-C-0114 |
|
May 4, 2010 |
January 1, 2019 |
June 30, 2019 |
May 26, 2010 |
March 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
38 |
NCT03454451 |
Recruiting |
CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers |
- Non-Small Cell Lung Cancer
- Renal Cell Cancer
- Colorectal Cancer
- (and 9 more...)
|
- Drug: CPI-006
- Drug: CPI-006 + CPI-444
- Drug: CPI-006 + pembrolizumab
|
Interventional |
Phase 1 |
- Corvus Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with CPI-444 and with pembrolizumab.
- Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with CPI-444 and with pembrolizumab.
- Identify the MDL(maximum dose level) of single agent CPI-006
- (and 3 more...)
|
378 |
All |
18 Years and older (Adult, Senior) |
NCT03454451 |
CPI-006-001 |
|
March 2018 |
March 2022 |
December 2023 |
March 6, 2018 |
March 29, 2018 |
|
- Carolina BioOncology Institute
Huntsville, North Carolina, United States
|
39 |
NCT03452774 |
Recruiting |
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
- Cancer, Metastatic
- Cancer
- Cancer of Pancreas
- (and 32 more...)
|
- Other: Clinical Trial Matching
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of patients Eligible for CTE versus Actual CTE
- Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis
- Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis
- (and 4 more...)
|
1500 |
All |
Child, Adult, Senior |
NCT03452774 |
SYNERGY-AI |
|
January 1, 2018 |
December 2021 |
December 2022 |
March 2, 2018 |
March 2, 2018 |
|
- Massive Bio, Inc
New York, New York, United States
|
40 |
NCT03301493 |
Recruiting |
Genomic Testing and Resulting Medical Decisions |
- Cancer of Unknown Origin
- Cancer Refractory
- Cancer of Stomach
- (and 12 more...)
|
|
Observational |
|
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Roche Pharma AG
|
Other / Industry |
- Observational Model: Other
- Time Perspective: Other
|
- Types of:molecular profiling methods
- Types of cancer, for which comprehensive molecular profiling is used
- Timing of molecular profiling
- (and 4 more...)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03301493 |
AGMT_NGS-Registry |
|
March 30, 2017 |
December 2019 |
December 2019 |
October 4, 2017 |
October 4, 2017 |
|
- Innere Medizin II, LKH Feldkirch
Feldkirch, Austria - Universitätsklinikum Krems
Krems an der Donau, Austria - IIIrd Medical Department, Private Medical University Hospital Salzburg
Salzburg, Austria
|
41 |
NCT03133286 |
Recruiting |
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) |
- Radiation Therapy
- Cancer
- Cancer of Anus
- (and 16 more...)
|
|
Observational |
|
- DxTerity Diagnostics
- National Cancer Institute (NCI)
|
Industry / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Obtain pre- and post-irradiation participant-collect blood samples
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03133286 |
DXT-RADTOX-AC03 HHSN261201600051C |
RADIANT |
April 6, 2017 |
September 6, 2018 |
September 6, 2018 |
April 28, 2017 |
May 4, 2017 |
|
- DxTerity Diagnostics
Compton, California, United States
|
42 |
NCT01846520 |
Recruiting |
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers |
- Healthy Subject
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- (and 81 more...)
|
- Other: educational intervention
- Behavioral: telephone-based intervention
- Procedure: quality-of-life assessment
- Other: questionnaire administration
|
Interventional |
Not Applicable |
- City of Hope Medical Center
- National Cancer Institute (NCI)
- American Cancer Society (ACS) National Office
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Effects of Family Caregiver Palliative Care Intervention (FCPCI) on caregiver burden
- Effects of FCPCI on caregiving skills preparedness
- Effects of FCPCI on Quality Of Life (QOL)
- (and 6 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT01846520 |
08176 NCI-2013-00839 |
|
October 2013 |
October 2023 |
October 2023 |
May 3, 2013 |
February 14, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
43 |
NCT01366144 |
Recruiting |
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction |
- Breast Carcinoma
- Carcinoma of Unknown Primary Origin
- Endometrial Carcinoma
- (and 7 more...)
|
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- Abbott
|
NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0
- PK parameters of veliparib
- Incidence of stable disease as assessed by RECIST version 1.1
- (and 3 more...)
|
276 |
All |
18 Years and older (Adult, Senior) |
NCT01366144 |
NCI-2011-02500 UPCI 10-115 CDR0000700997 UPCI-10-115 8808 N01CM00100 P30CA047904 U01CA062490 U01CA062502 U01CA062505 U01CA069856 U01CA070095 U01CA099168 UM1CA186690 UM1CA186691 UM1CA186709 UM1CA186717 |
|
June 20, 2011 |
July 31, 2017 |
|
June 3, 2011 |
July 26, 2017 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - City of Hope South Pasadena
South Pasadena, California, United States - (and 14 more...)
|
44 |
NCT00004074 |
Completed |
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
- Advanced Adult Primary Liver Cancer
- Anaplastic Thyroid Cancer
- Bone Metastases
- (and 124 more...)
|
- Biological: recombinant interleukin-12
- Biological: ABI-007/carboplatin/trastuzumab
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT00004074 |
NCI-2012-01398 99H0185 U01CA076576 CDR0000067282 |
|
August 1999 |
February 2009 |
|
October 29, 2003 |
February 28, 2013 |
|
- Ohio State University Medical Center
Columbus, Ohio, United States
|
45 |
NCT01654068 |
Active, not recruiting |
Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine |
|
- Radiation: Conformal High Dose Intensity Modulated Radiation Therapy
|
Interventional |
Phase 2 |
- Ronald McGarry
- University of Kentucky
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to any skeletal related event
- Acute Radiation Toxicity
- Late Radiation Toxicity
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT01654068 |
09-RAD-01 |
|
December 2009 |
July 2020 |
July 2020 |
July 31, 2012 |
August 4, 2017 |
|
- University of Kentucky
Lexington, Kentucky, United States
|
46 |
NCT01176500 |
Withdrawn |
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors |
- Colon Cancer
- Lung Cancer
- Cervical Cancer
- (and 2 more...)
|
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
- GE Healthcare
|
NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To determine tumor uptake and retention of [18F]fluciclatide before and after 1 cycle of treatment with targeted anti-angiogenic therapy.
- To obtain preliminary data on the relationships between [18F]fluciclatide as a pharmacodynamic marker and standard of care imaging markers of clinical response.
- To assess the safety of multiple intravenous (IV) administrations of Fluciclatide [18F] Injection in subjects with solid tumors.
|
0 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01176500 |
100173 10-C-0173 |
|
July 28, 2010 |
November 18, 2011 |
November 18, 2011 |
August 6, 2010 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
47 |
NCT03355976 |
Not yet recruiting |
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas |
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
- (and 2 more...)
|
- Drug: Nivolumab
- Drug: Ipilimumab
|
Interventional |
Phase 2 |
- Don Dizon
- Bristol-Myers Squibb
- Rhode Island Hospital
- (and 3 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab
- Compare median PFS for patients treated with nivolumab (Arm 1) and the combination of nivolumab and ipilimumab (Arm 2)
|
62 |
All |
18 Years and older (Adult, Senior) |
NCT03355976 |
BrUOG 354 |
|
February 2018 |
February 2020 |
February 2022 |
November 29, 2017 |
November 30, 2017 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States - The Miriam Hospital
Providence, Rhode Island, United States
|
48 |
NCT03382158 |
Recruiting |
International PPB Registry for PPB, DICER1 and Associated Conditions |
- Pleuropulmonary Blastoma
- Sertoli-Leydig Cell Tumor
- DICER1 Syndrome
- (and 10 more...)
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Washington University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Event-free survival
- Overall response to chemotherapy
- Overall survival
- (and 4 more...)
|
100 |
All |
Child, Adult, Senior |
NCT03382158 |
FDAAA |
|
December 6, 2016 |
December 6, 2023 |
December 6, 2026 |
December 22, 2017 |
December 22, 2017 |
|
- Children;s Minnesota
Minneapolis, Minnesota, United States
|
49 |
NCT03215511 |
Recruiting |
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers |
- Carcinoma, Non-Small-Cell Lung
- Thyroid Neoplasms
- Sarcoma
- (and 32 more...)
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Recommended dose for further study in patients age 12 and older and age <12
- Best overall response of confirmed PR or CR by independent radiology review in patients age 12 and older and age <12 in NTRK fusion cancer patients previously treated with TRK inhibitor who have progressed
- (and 14 more...)
|
93 |
All |
1 Month and older (Child, Adult, Senior) |
NCT03215511 |
LOXO-EXT-17005 |
|
July 10, 2017 |
August 2019 |
December 2019 |
July 12, 2017 |
March 1, 2018 |
|
- Stanford Cancer Center
Stanford, California, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - MD Anderson Cancer Center
Houston, Texas, United States
|
50 |
NCT03154190 |
Recruiting |
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer |
- Acute Myeloid Leukemia
- Brain Glioblastoma
- Estrogen Receptor Negative
- (and 64 more...)
|
- Other: Best Practice
- Other: Laboratory Biomarker Analysis
- Procedure: Supportive Care
- Other: Survey Administration
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Emergency Department Visit (Chart Review)
- Hospitalization Visits (Chart Review)
- Hospice Consult (Chart Review)
- (and 4 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03154190 |
VAR0134 |
|
December 15, 2016 |
November 30, 2018 |
November 30, 2019 |
May 16, 2017 |
May 16, 2017 |
|
- Virginia K Crosson Cancer Center
Fullerton, California, United States
|